Pancreatic cancer action network - Join us
Clinical Trial
Finder
Retrieving Trials
Retrieving Trials...

Back to Trial Search

Phase Ib Dose-Escalation Study of Palbociclib and Nab-Paclitaxel (Abraxane) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Summary

NOTE: Sites are enrolling in either Part A or Part B; please call the site to confirm. The purpose of this Phase I study is to determine the safety and tolerability of palbociclib in combination with nab-paclitaxel, in sequential cohorts of adult patients with metastatic pancreatic ductal adenocarcinoma.

General Information

NCT#: NCT02501902
Study ID: A5481059
Trial Phase: Phase I

Trial Sponsor: Pfizer, Celgene Corporation
Therapies Used in This Trial: Nab-paclitaxel, Palbociclib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account?

Request an Account


  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account.
  • In order to view this information, you need to be signed in as a Health Care Provider.
  • In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
  • This information is restricted to validated Health Care Providers.

Eligibility



-------------------------------------------------------------------------------------------

  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
  • ------------------------------------------------------------------------------------------------------
  • In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information


Back to Trial Search